Vaxcyte, Inc. — Director's Dealing 2021

Jan 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-01-15

Reporting Person: Wright-Mitchell Jane (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-15	Common Stock	M	2500	$2.03	Acquired	4062	Direct
2021-01-15	Common Stock	S	2500	$26.00	Disposed	1562	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-15	Stock Option (right to buy)	$2.03	M	2500	Disposed	2029-03-20	Common Stock (2500)	Direct

Footnotes

F1: Includes 1,562 shares acquired under the Employee Stock Purchase Plan on November 17, 2020.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3: 1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter.